AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 237 filers reported holding AMICUS THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 0.37 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $12,935,881 | -3.2% | 1,063,806 | 0.0% | 0.35% | +9.1% |
| Q2 2023 | $13,361,403 | +13.3% | 1,063,806 | 0.0% | 0.32% | +13.2% |
| Q1 2023 | $11,797,609 | -9.2% | 1,063,806 | 0.0% | 0.28% | -10.2% |
| Q4 2022 | $12,989,071 | +22.9% | 1,063,806 | +5.1% | 0.31% | +14.7% |
| Q3 2022 | $10,571,000 | -2.8% | 1,012,506 | 0.0% | 0.27% | -13.6% |
| Q2 2022 | $10,874,000 | +13.4% | 1,012,506 | 0.0% | 0.32% | +31.1% |
| Q1 2022 | $9,588,000 | -18.0% | 1,012,506 | 0.0% | 0.24% | -10.7% |
| Q4 2021 | $11,694,000 | +20.9% | 1,012,506 | 0.0% | 0.27% | +33.0% |
| Q3 2021 | $9,669,000 | -0.9% | 1,012,506 | 0.0% | 0.20% | +5.2% |
| Q2 2021 | $9,761,000 | -2.4% | 1,012,506 | 0.0% | 0.19% | -11.5% |
| Q1 2021 | $10,004,000 | -57.9% | 1,012,506 | -1.6% | 0.22% | -56.7% |
| Q4 2020 | $23,760,000 | +64.4% | 1,029,000 | +0.5% | 0.50% | +37.3% |
| Q3 2020 | $14,456,000 | -5.7% | 1,023,821 | +0.7% | 0.37% | -12.8% |
| Q2 2020 | $15,334,000 | +66.0% | 1,016,821 | +1.7% | 0.42% | +10.2% |
| Q1 2020 | $9,240,000 | -5.1% | 1,000,000 | 0.0% | 0.38% | +24.0% |
| Q4 2019 | $9,740,000 | +21.4% | 1,000,000 | 0.0% | 0.31% | -3.8% |
| Q3 2019 | $8,020,000 | -35.7% | 1,000,000 | 0.0% | 0.32% | -29.2% |
| Q2 2019 | $12,480,000 | -8.2% | 1,000,000 | 0.0% | 0.45% | -13.7% |
| Q1 2019 | $13,600,000 | +42.0% | 1,000,000 | 0.0% | 0.52% | +15.9% |
| Q4 2018 | $9,580,000 | -20.8% | 1,000,000 | 0.0% | 0.45% | +3.2% |
| Q3 2018 | $12,090,000 | -22.6% | 1,000,000 | 0.0% | 0.44% | -27.1% |
| Q2 2018 | $15,620,000 | +3.9% | 1,000,000 | 0.0% | 0.60% | -6.4% |
| Q1 2018 | $15,040,000 | +14.9% | 1,000,000 | +9.9% | 0.64% | +8.1% |
| Q4 2017 | $13,095,000 | -4.6% | 910,000 | 0.0% | 0.59% | -6.2% |
| Q3 2017 | $13,723,000 | +79.9% | 910,000 | +20.1% | 0.63% | +64.4% |
| Q2 2017 | $7,628,000 | +41.2% | 757,500 | 0.0% | 0.38% | +23.4% |
| Q1 2017 | $5,401,000 | +43.5% | 757,500 | 0.0% | 0.31% | +23.8% |
| Q4 2016 | $3,765,000 | -26.8% | 757,500 | +9.0% | 0.25% | -21.7% |
| Q3 2016 | $5,143,000 | +38.5% | 695,000 | +2.2% | 0.32% | +17.1% |
| Q2 2016 | $3,713,000 | -28.4% | 680,000 | +10.8% | 0.28% | -36.6% |
| Q1 2016 | $5,184,000 | -5.7% | 613,500 | +8.3% | 0.43% | +4.3% |
| Q4 2015 | $5,495,000 | -13.7% | 566,500 | +24.5% | 0.42% | -19.5% |
| Q3 2015 | $6,365,000 | +19.2% | 455,000 | +20.5% | 0.52% | +32.6% |
| Q2 2015 | $5,342,000 | – | 377,500 | – | 0.39% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |